Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-10-16
DOI
10.3389/fonc.2021.727010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update
- (2021) Shuja Sheikh et al. Journal of Clinical Medicine
- Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature
- (2020) Chiara Demichelis et al. NEUROLOGICAL SCIENCES
- Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies
- (2020) Elia Sechi et al. Journal of Thoracic Oncology
- Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies
- (2019) Annette Johansen et al. NEUROLOGY
- Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
- (2019) Atsushi Tanaka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma
- (2019) Austin Zaloum et al. NEUROLOGY
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent
- (2018) Aaron Desai et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Kinase-targeted cancer therapies: progress, challenges and future directions
- (2018) Khushwant S. Bhullar et al. Molecular Cancer
- Lambert-Eaton Myasthenic Syndrome
- (2018) Vita G. Kesner et al. NEUROLOGIC CLINICS
- Myasthenia gravis unmasked by imatinib
- (2018) Chirag R. Kopp et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
- (2018) Marvin Kuske et al. PHARMACOLOGICAL RESEARCH
- Repetitive nerve stimulation test in myasthenic crisis
- (2018) Shin J. OH et al. MUSCLE & NERVE
- Immunotherapy in myasthenia gravis in the era of biologics
- (2018) Marinos C. Dalakas Nature Reviews Neurology
- Regulatory T cells in multiple sclerosis and myasthenia gravis
- (2017) K. M. Danikowski et al. Journal of Neuroinflammation
- Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab
- (2017) Dagur Ingi Jonsson et al. NEUROMUSCULAR DISORDERS
- Therapeutic immune monitoring of CD4+CD25+ T cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
- (2017) Ziyuan Lu et al. Oncology Letters
- Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment
- (2016) Paolo E. Alboini et al. MUSCLE & NERVE
- Myasthenia Gravis
- (2016) Nils E. Gilhus NEW ENGLAND JOURNAL OF MEDICINE
- Changes in inflammatory cytokine networks in myasthenia gravis
- (2016) Akiyuki Uzawa et al. Scientific Reports
- Ten things you should know about protein kinases: IUPHAR Review 14
- (2015) Doriano Fabbro et al. BRITISH JOURNAL OF PHARMACOLOGY
- MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu
- (2015) Dewan M. S. Hossain et al. IMMUNOLOGY
- Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors
- (2015) Nora V. Lieske et al. PLoS One
- Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool
- (2014) J. Christoph Vahl et al. IMMUNITY
- Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors
- (2014) N. Larmonier et al. JOURNAL OF IMMUNOLOGY
- MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4
- (2013) M. G. Huijbers et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
- (2012) Vandana Lamba et al. CURRENT PHARMACEUTICAL DESIGN
- Changes of Treg-Associated Molecules on CD4+CD25+Treg Cells in Myasthenia Gravis and Effects of Immunosuppressants
- (2012) Wen-Hua Xu et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine
- (2012) Konstantinos Poulas et al. JOURNAL OF NEUROIMMUNOLOGY
- Regulatory T cells and Foxp3
- (2011) Alexander Y. Rudensky IMMUNOLOGICAL REVIEWS
- T Cell-Signaling Network Analysis Reveals Distinct Differences between CD28 and CD2 Costimulation Responses in Various Subsets and in the MAPK Pathway between Resting and Activated Regulatory T Cells
- (2011) Maria Elisabeth Kalland et al. JOURNAL OF IMMUNOLOGY
- Increased serum interleukin-17 levels in patients with myasthenia gravis
- (2011) Jose C. Roche et al. MUSCLE & NERVE
- Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome
- (2011) T. J. Lehky et al. NEUROLOGY
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Muscle Specific Kinase: Organiser of synaptic membrane domains
- (2010) Nazanin Ghazanfari et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Lck is a key target of imatinib and dasatinib in T-cell activation
- (2010) K C Lee et al. LEUKEMIA
- Effects of nilotinib on regulatory T cells: the dose matters
- (2010) Fei Fei et al. Molecular Cancer
- Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib
- (2008) Elizabeth Day et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells
- (2008) T. Korn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More